AgingNCT07500649
Project SIRT6 Activator
A study testing Fucoidan in people with Aging, run by National University of Singapore at 2 sites in Singapore.
Trial summary
The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. Read more about this study
- Who is it for?
- Ages 50 to 80 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Aging
- What is being tested?
- Fucoidan
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 2 sitesSingapore
- Study dates
- 1 Jul 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 50-80 years males;
- Resident of Singapore (citizenship or permanent residency is not required);
- Prefrail according to Fried frailty phenotype score;
- English-literate who can understand, read and write in English;
- Individuals without severe cognitive impairment, as determined by PI judgment;
- Apparently healthy and non-smokers having not more than 2 of the following conditions. If the conditions are present they have to be stable:
Show all 14Show fewer
- Hypertension,
- Hyperlipidemia,
- Hyperglycemia,
- Osteopenia/osteoporosis,
- Osteoarthritis,
- COPD,
- Type 2 diabetes.
- Subjects who agree to shave one day before each visit if he has dense facial hairs on their cheeks that could interfere with skin microbiome sampling.
Who cannot join
- Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease);
- Current cancer or non-stable chronic obstructive pulmonary disease (COPD);
- Use of anticoagulant medication;
- Consuming seaweed more than 3 times a week;
- Having hairiness, moles, tattoos, scars, irritated skin, etc. on the face which could influence the investigation;
- Having used within the 3 past weeks for more than 3 consecutive days any systemic or topical drugs related to antibiotics or having planned to use these treatments during the study;
Show all 13Show fewer
- Having a positive serology for HIV, HEPATITIS B, HEPATITIS C*
- Subjects will undergo a serology test, which will be conducted at baseline and at the end of the intervention visit. Only for subjects who accepted to undergo skin microbiopsy sampling;
- Subject with any contra-indication for skin microbiopsies:
- hypersensitivity or any serious reaction to local anesthesia; (lidocaine/prilocaine), local antibiotics, and antiseptics,
- with inherited or acquired hemostasis disorders,
- having had any treatment which may affect the blood coagulation and hemostasis (anti-coagulant medications…),
- having a history of wound healing defects (hypertrophic scars, keloids…).
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore2 sites, 2 recruiting
- Recruiting
Yong Loo Lin School of Medicine, National University of Singapore
Singapore, Singapore, 117597
Andrea Britta Maier, doctor, (65) 87142729, longevitytrials@nus.edu.sg
- Not yet recruiting
NUS Academy for Healthy Longevity, Level 6, MD 11, 10 Medical Dr, Yong Loo Lin School of Medicine, National University of Singapore
Singapore
Andrea Britta Maier, MD PhD FRACP, 6563793186, a.maier@nus.edu.sg
Hodzic Kuerec Ajla, MD PhD, +65 98376777, ahkuerec@nus.edu.sg
About this study
Official title: SIRT6 Activation to Improve Biological Age Measured by GrimAge in Pre-frail, Middle-aged to Older Men: a Randomized Controlled Trial
The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.
Read the detailed description
Ageing is driven by several interconnected mechanisms, including deoxyribonucleic acid (DNA) damage, mitochondrial dysfunction, depletion of nicotinamide adenine dinucleotide (NAD+) levels, impaired autophagy, stem cell exhaustion, chronic inflammation, loss of protein homeostasis, deregulated nutrient sensing, altered intercellular communication, and microbiome imbalance. Sirtuin 6 (SIRT6) an NAD+ dependent deacetylase and ADP-ribosyl-transferase, has emerged as a pivotal factor in the regulation of several of these mechanisms, including DNA repair, metabolism, and inflammation. Long-lived species have higher SIRT6 activity. Potent and safe SIRT6 activators have the potential to extend human lifespan and healthspan.
Fucoidan, a polymer of L-fucose and L-fucose-4-sulfate derived from brown macroalgae is available as a dietary supplement, safe for human consumption, and rarely causes irritation. Fucoidan exhibits dose-dependent SIRT6-stimulating activity and extends lifespan in model organisms. Inflammation is associated with higher biological age and poor health outcomes, including frailty. In an open-label single-arm clinical study where 400 ml (10mg/ml) fucoidan was administered to 20 cancer patients (mean age 58.9 years) reported a decrease in the interleukin (IL) levels (IL-6, IL-1-beta) and tumour necrosis factor (TNF)-alpha, after 2 weeks compared to baseline levels. In addition, studies found that fucoidan modulates DNA methylation (DNAm) in vitro and in vivo and play a role of inhibiting carcinogenesis. Currently, there is no data about the effect of fucoidan on DNAm in humans.
Therefore, this study will investigate the effects of a SIRT6 activator, compared to a placebo, on DNAm assessed by GrimAge in 60 prefrail, middle-aged to older (50-80 years) healthy males.
The aim is to evaluate the geroprotective effect of a SIRT6 activator and determine whether it can modulate biological pathways of ageing. The investigators hypothesize that supplementation with a SIRT6 activator (2.4 g/day/6 months) will decrease DNAm as assessed by GrimAge in prefrail, middle-aged to older (50-80 years), males and improve biological (inflammatory, glycans) and clinical markers of ageing (frailty, quality of life, sleep, cognitive, body composition, muscular, cardiovascular, and reproductive and skin ageing).
Study objectives: to assess the effect of supplementation with a SIRT6 activator (2.4 g/day/6 months) on biological (epigenetic inflammatory, glycans) and clinical markers of ageing (frailty, quality of life, sleep, cognitive, body composition, muscular, cardiovascular, reproductive and skin ageing) compared to placebo in 60 prefrail, middle-aged to older (50-80 years), males.
- Conditions
- Aging
- Being tested
- Fucoidan, Placebo
- Keywords
- Aging, Geroscience, Fucoidan, SIRT6 Activator, DNA methylation, Healthspan, Epigenetic aging clock
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FucoidanDietary supplement
Eligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.
PlaceboDietary supplement
Eligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months.
| Study group | Role | What they receive |
|---|---|---|
| SIRT6 activator | Experimental | Participants in this arm will take 2.4 g/day of Fucoidan (or known as SIRT6 activator) supplement for 6 months Receives: Dietary Supplement: Fucoidan |
| Placebo | Placebo comparator | Participants in this arm will take 2.4 g/day of placebo for 6 months Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in blood DNA methylation status, years
DNA methylation aging clock
Measured: from baseline to end of intervention (6 months)
Secondary outcomes (33)
Change in blood inflammatory markers (pg/mL)
comparison of inflammatory markers: IL-10, IFN-γ，IL-17, TNF-a, IL-6，CXCL9 (pg/mL) at baseline, interim and end-of-trial
Measured: from baseline to end of intervention (6 months)
Body Mass Index (BMI) change
comparison of BMI at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Waist-to-hip ratio change
comparison of waist-to-hip ratio at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Body fat mass (kg) change
comparison of body fat mass at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Skeletal muscle mass (kg) change
comparison of skeletal muscle mass at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Percentage body fat (%) change
comparison of percentage body fat at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Systolic blood pressure (mm Hg) change
comparison of systolic blood pressure at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Diastolic blood pressure (mm Hg) change
comparison of diastolic blood pressure at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Pulse rate (BPM) change
comparison of pulse rate at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Skin elasticity (mm/time) change
comparison of skin elasticity measured by he resistance of the skin to the negative pressure (firmness) and its ability to return into its original position (elasticity) displayed as curves (penetration depth in mm/time) at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Skin colour (L* a* b*) change
comparison of skin colour measured using automatic calculation of ITA (Individual Typology Angle) that uses CIE L* a* b* values to classify 6 skin colours from very light to dark at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Skin autofluorescence (au) change
comparison of skin autofluorescence levels calculated by dividing the mean value of the emitted light intensity per nm between 420 and 600 nm by the mean value of the excitation light intensity per nm between 300 and 420 nm, expressed in arbitrary units (AU) at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Skin evaluation: microbiopsies for proteomics
Measured: from baseline to end of intervention (6 months)
Complete blood count: lymphocytes_countm, neutrophils_count, monocyte_count, basophil_count, eosinphil_count, WBC_count,PLT_count (*10^9/L)
comparison of blood count at baseline, interim and end-of-trial.
Measured: from baseline to end of intervention (6 months)
Change in cognition (Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Test)
comparison of cognition at baseline, interim and end of trial. A RBANS result range from 40-160, the higher scale indicates the better congnition function.
Measured: from baseline to end of intervention (6 months)
Change in Physical Activity (Minnesota Leisure Time Activity Questionnaire)
comparison of physical activity at baseline, interim and end of trial. The higher the value (energy expenditure or time), the higher the level of physical activity during leisure time.
Measured: from baseline to end of intervention (6 months)
Change in Exhaustion [Center for Epidemiologic Studies Depression Scale (CES-D)]
CES-D scale range from 0-60. The higher the score, the more severe the depressive symptoms. comparison of exhaustion at baseline, interim and end of trial.
Measured: from baseline to end of intervention (6 months)
Change in dietary intake (3-day Food Record)
comparison of dietary intake at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Change in quality of life 36-Item Short Form Survey (SF-36)
comparison of quality of life 36-Item Short Form Survey (SF-36) at baseline, interim and end of trial. SF-36_overall range from 0-100, the larger scale indicates the better quality of life.
Measured: from baseline to end of intervention (6 months)
Change in Depression, anxiety and/ or stress levels [Depression Anxiety and Stress Scale (21 items) (DASS-21)]
DASS-21 scale ranges from 0-21. The higher the score, the more severe the symptoms in that dimension are. comparison of depression, anxiety and/ or stress levels at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Change in Reproductive health [Androgen Deficiency in Aging Males (ADAM) questionnaire]
Androgen Deficiency in Aging Males (ADAM) questionnaire scale ranges from 0-10. A "Positive" result indicates a high likelihood of androgen deficiency, warranting further clinical evaluation (e.g., testosterone testing). comparison of reproductive health at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Change in sleep quality (modified Pittsburgh Sleep Quality Questionnaire)
modified Pittsburgh Sleep Quality Questionnaire scale ranges from 0-21. Higher total scores indicate worse sleep quality. comparison of sleep quality at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Change in handgrip strength change (kg)
comparison of handgrip strength at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Change in 8-RM leg extension change (kg)
comparison of 8-RM leg extension at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Carotid-femoral Pulse Wave Velocity change
comparison of carotid-femoral pulse wave velocity at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Central Blood pressure change
comparison of central Blood pressure at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Change in blood inflammatory markers:hs-CRP (mg/mL)
Measured: basline, 3 months, and 6 months
Change in quality of life: EuroQol-D5-5L (EQ-5D)
A 5-digit code describing a health state. This code is then converted to a single index number using a country-specific value set (a formula based on public preferences). comparison of quality of life of EQ-5D at baseline, interim and end of trial
Measured: from baseline to end of intervention (6 months)
Skin micobiopsies for microbiomics.
Measured: Time Frame: from baseline to the end of the trial (6 months)
Skin micobiopsies: Transcriptomics
Measured: from baseline to the end of ths study (6 months)
skin microbiopsies evaluation: DNA methylation
Measured: from baseline to the end of this study (6 months)
Complete blood count: red blood cell_count (*10^12/L)
comparison of blood count at baseline, interim and end-of-trial.
Measured: from baseline to end of intervention (6 months)
Complete blood count: Hemoglobulin (*g/L)
comparison of blood count at baseline, interim and end-of-trial.
Measured: Time Frame: from baseline to end of intervention (6 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study start1 Jul 2025
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- University of Rochester, L'Oreal, DoNotAge.org
- Responsible party
- Principal investigator, Andrea Maier, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07500649
- Sponsor's protocol ID
- NUS-IRB-2024-806
- Status last verified
- Mar 2026
- First submitted
- 10 Feb 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SIRT6 Activation to Improve Biological Age Measured by GrimAge in Pre-frail, Middle-aged to Older Men: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07500649
- Acronym / sponsor ID
- NUS-IRB-2024-806
- Conditions
- Aging
- Keywords
- Aging, Geroscience, Fucoidan, SIRT6 Activator, DNA methylation, Healthspan, Epigenetic aging clock
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Collaborators
- University of Rochester, L'Oreal, DoNotAge.org
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.
Detailed description
Ageing is driven by several interconnected mechanisms, including deoxyribonucleic acid (DNA) damage, mitochondrial dysfunction, depletion of nicotinamide adenine dinucleotide (NAD+) levels, impaired autophagy, stem cell exhaustion, chronic inflammation, loss of protein homeostasis, deregulated nutrient sensing, altered intercellular communication, and microbiome imbalance. Sirtuin 6 (SIRT6) an NAD+ dependent deacetylase and ADP-ribosyl-transferase, has emerged as a pivotal factor in the regulation of several of these mechanisms, including DNA repair, metabolism, and inflammation. Long-lived species have higher SIRT6 activity. Potent and safe SIRT6 activators have the potential to extend human lifespan and healthspan.
Fucoidan, a polymer of L-fucose and L-fucose-4-sulfate derived from brown macroalgae is available as a dietary supplement, safe for human consumption, and rarely causes irritation. Fucoidan exhibits dose-dependent SIRT6-stimulating activity and extends lifespan in model organisms. Inflammation is associated with higher biological age and poor health outcomes, including frailty. In an open-label single-arm clinical study where 400 ml (10mg/ml) fucoidan was administered to 20 cancer patients (mean age 58.9 years) reported a decrease in the interleukin (IL) levels (IL-6, IL-1-beta) and tumour necrosis factor (TNF)-alpha, after 2 weeks compared to baseline levels. In addition, studies found that fucoidan modulates DNA methylation (DNAm) in vitro and in vivo and play a role of inhibiting carcinogenesis. Currently, there is no data about the effect of fucoidan on DNAm in humans.
Therefore, this study will investigate the effects of a SIRT6 activator, compared to a placebo, on DNAm assessed by GrimAge in 60 prefrail, middle-aged to older (50-80 years) healthy males.
The aim is to evaluate the geroprotective effect of a SIRT6 activator and determine whether it can modulate biological pathways of ageing. The investigators hypothesize that supplementation with a SIRT6 activator (2.4 g/day/6 months) will decrease DNAm as assessed by GrimAge in prefrail, middle-aged to older (50-80 years), males and improve biological (inflammatory, glycans) and clinical markers of ageing (frailty, quality of life, sleep, cognitive, body composition, muscular, cardiovascular, and reproductive and skin ageing).
Study objectives: to assess the effect of supplementation with a SIRT6 activator (2.4 g/day/6 months) on biological (epigenetic inflammatory, glycans) and clinical markers of ageing (frailty, quality of life, sleep, cognitive, body composition, muscular, cardiovascular, reproductive and skin ageing) compared to placebo in 60 prefrail, middle-aged to older (50-80 years), males.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SIRT6 activator | Experimental | Dietary Supplement: FucoidanParticipants in this arm will take 2.4 g/day of Fucoidan (or known as SIRT6 activator) supplement for 6 months |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants in this arm will take 2.4 g/day of placebo for 6 months |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- 50-80 years males;
- Resident of Singapore (citizenship or permanent residency is not required);
- Prefrail according to Fried frailty phenotype score;
- English-literate who can understand, read and write in English;
- Individuals without severe cognitive impairment, as determined by PI judgment;
Key exclusion criteria (13 listed)
- Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease);
- Current cancer or non-stable chronic obstructive pulmonary disease (COPD);
- Use of anticoagulant medication;
- Consuming seaweed more than 3 times a week;
- Having hairiness, moles, tattoos, scars, irritated skin, etc. on the face which could influence the investigation;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FucoidanEligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months. | Dietary supplement | SIRT6 activator |
| PlaceboEligible participants will be randomized to receive SIRT6 Activator (fucoidan) or Placebo for 6 months. | Dietary supplement | Placebo |
Primary outcome
Change in blood DNA methylation status, years
Time frame: from baseline to end of intervention (6 months)
DNA methylation aging clock
33 secondary outcomes
Change in blood inflammatory markers (pg/mL)
Time frame: from baseline to end of intervention (6 months)
Body Mass Index (BMI) change
Time frame: from baseline to end of intervention (6 months)
Waist-to-hip ratio change
Time frame: from baseline to end of intervention (6 months)
Body fat mass (kg) change
Time frame: from baseline to end of intervention (6 months)
Skeletal muscle mass (kg) change
Time frame: from baseline to end of intervention (6 months)
Percentage body fat (%) change
Time frame: from baseline to end of intervention (6 months)
Systolic blood pressure (mm Hg) change
Time frame: from baseline to end of intervention (6 months)
Diastolic blood pressure (mm Hg) change
Time frame: from baseline to end of intervention (6 months)
Pulse rate (BPM) change
Time frame: from baseline to end of intervention (6 months)
Skin elasticity (mm/time) change
Time frame: from baseline to end of intervention (6 months)
Skin colour (L* a* b*) change
Time frame: from baseline to end of intervention (6 months)
Skin autofluorescence (au) change
Time frame: from baseline to end of intervention (6 months)
Skin evaluation: microbiopsies for proteomics
Time frame: from baseline to end of intervention (6 months)
Complete blood count: lymphocytes_countm, neutrophils_count, monocyte_count, basophil_count, eosinphil_count, WBC_count,PLT_count (*10^9/L)
Time frame: from baseline to end of intervention (6 months)
Change in cognition (Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Test)
Time frame: from baseline to end of intervention (6 months)
Change in Physical Activity (Minnesota Leisure Time Activity Questionnaire)
Time frame: from baseline to end of intervention (6 months)
Change in Exhaustion [Center for Epidemiologic Studies Depression Scale (CES-D)]
Time frame: from baseline to end of intervention (6 months)
Change in dietary intake (3-day Food Record)
Time frame: from baseline to end of intervention (6 months)
Change in quality of life 36-Item Short Form Survey (SF-36)
Time frame: from baseline to end of intervention (6 months)
Change in Depression, anxiety and/ or stress levels [Depression Anxiety and Stress Scale (21 items) (DASS-21)]
Time frame: from baseline to end of intervention (6 months)
Change in Reproductive health [Androgen Deficiency in Aging Males (ADAM) questionnaire]
Time frame: from baseline to end of intervention (6 months)
Change in sleep quality (modified Pittsburgh Sleep Quality Questionnaire)
Time frame: from baseline to end of intervention (6 months)
Change in handgrip strength change (kg)
Time frame: from baseline to end of intervention (6 months)
Change in 8-RM leg extension change (kg)
Time frame: from baseline to end of intervention (6 months)
Carotid-femoral Pulse Wave Velocity change
Time frame: from baseline to end of intervention (6 months)
Central Blood pressure change
Time frame: from baseline to end of intervention (6 months)
Change in blood inflammatory markers:hs-CRP (mg/mL)
Time frame: basline, 3 months, and 6 months
Change in quality of life: EuroQol-D5-5L (EQ-5D)
Time frame: from baseline to end of intervention (6 months)
Skin micobiopsies for microbiomics.
Time frame: Time Frame: from baseline to the end of the trial (6 months)
Skin micobiopsies: Transcriptomics
Time frame: from baseline to the end of ths study (6 months)
skin microbiopsies evaluation: DNA methylation
Time frame: from baseline to the end of this study (6 months)
Complete blood count: red blood cell_count (*10^12/L)
Time frame: from baseline to end of intervention (6 months)
Complete blood count: Hemoglobulin (*g/L)
Time frame: Time Frame: from baseline to end of intervention (6 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
RecruitingPhase 4
PLLA and CaHA-R for Aesthetic Rejuvenation
Aesthetic
RecruitingObservational study
Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)
Healthy Volunteers, Non-Healthy/Non-Frail
Recruiting
Exercise for an Aging Liver (EXALIVER)
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fucoidan in people with Aging, run by National University of Singapore at 2 sites in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrea Britta Maier, MD PhD (+65 63793186, a.maier@nus.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in blood DNA methylation status, years (time frame: from baseline to end of intervention (6 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.